Hypertrophic cardiomyopathy (HCM) is a disease of the heart muscles (myocardium) in which thickening of myocardium causes functional impairment. It is a genetic condition caused by mutation in one or more genes and is hereditary in nature. According to the European Society of Cardiology, prevalence of HCM was between 0.05% and 0.2% of the population in 2013. A study published in BioMed Central in 2010 stated that there was no significant gender and age range differences in the prevalence of HCM. The global hypertrophic cardiomyopathy therapeutics market has been broadly categorized into drug class and geography. Beta adrenergic blocking agents, calcium channel blockers, antiarrhythmic agents, and anticoagulants together constitute the drugs class segment of the hypertrophic cardiomyopathy therapeutics market.

1. Hypertrophic Cardiomyopathy Therapeutics Market -
Global Industry Analysis, Pipeline Analysis, Size, Share,
Growth, Trends, and Forecast, 2015 – 2023
Published By:
Transparency Market
Research
Contact US:
Tel: +1-518-618-1030
Email: sales@mrrse.com
Toll Free : 866-997-4948 (US-
CANADA)

2. Report Description
Hypertrophic cardiomyopathy (HCM) is a disease of the heart muscles (myocardium) in which thickening
of myocardium causes functional impairment. It is a genetic condition caused by mutation in one or more
genes and is hereditary in nature. According to the European Society of Cardiology, prevalence of HCM
was between 0.05% and 0.2% of the population in 2013. A study published in BioMed Central in 2010
stated that there was no significant gender and age range differences in the prevalence of HCM.
The global hypertrophic cardiomyopathy therapeutics market has been broadly categorized into drug class
and geography. Beta adrenergic blocking agents, calcium channel blockers, antiarrhythmic agents, and
anticoagulants together constitute the drugs class segment of the hypertrophic cardiomyopathy
therapeutics market. Calcium channel blockers was the largest segment in 2014, although beta adrenergic
blocking agents were the first choice for treatment of obstructive and non-obstructive HCM. Price of
calcium channel blockers is higher than beta adrenergic blocking agents; hence, in terms of revenue,
calcium channel blockers dominated the hypertrophic cardiomyopathy therapeutics market in 2014. A
similar trend is expected to continue during the forecast period. Calcium channel blockers are anticipated
to expand at a CAGR of 1.8% from 2015 to 2023.
Complete Report with TOC @ http://www.mrrse.com/hypertrophic-cardiomyopathy-therapeutics-market

3. Scope
Prevalence of HCM is higher among African-Americans compared to other races. The global hypertrophic
cardiomyopathy therapeutics market was valued at USD 1,216.3 million in 2014 and is projected to reach
USD 1,378.4 million by 2023, expanding at a CAGR of 1.4% during the forecast period.A similar trend is
expected to continue during the forecast period. Calcium channel blockers are anticipated to expand at a
CAGR of 1.8% from 2015 to 2023.

4. Key Players
AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva
Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG are some of the major
companies operating in the global hypertrophic cardiomyopathy therapeutics market.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1418

5. Corporate Office
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@mrrse.com
Toll Free : 866-997-4948 (US-CANADA)
Contact Us
Read More @ http://www.mrrse.com/